Last Updated on December 8, 2021 by The Health Master
Mumbai-based BDR Pharma has announced the launch of India’s first generic- Midostaurin under the brand name MSTARIN, which is indicated in rare, hard-to-treat cancers.
The drug is approved for use in combination with standard Daunorubicin & Cytarabine induction and high-dose Cytarabine consolidation chemotherapy
And for patients in complete response followed by Midostaurin single-agent maintenance therapy for adults with newly diagnosed Acute Myeloid Leukemia (AML) who are FLT3 mutation-positive.
The drug will have a strength of 25 mg, in the form of capsules.
BDR Pharma launches Antibiotics to treat these infections
Natco Pharma launches FDC Trifluridine & Tipiracil first time in India
MSN Labs launches Vigabatrin Powder for the treatment of Epilepsy
A portable Hydrogen inhaler launched: Dual-use technology
Lupin launches generic Fenofibrate capsules for this ailment
Sun Pharma launches acne treatment cream
NPPA fixes retail price of 20 formulations: December 2021
IPC adds these 9 new IP impurities standards
Lok Sabha passes NIPER (Amendment) Bill 2021
India and Pharmacy Education: Chapter: 10
68 cases of unapproved Fixed Dose Combinations reported during 2017-21
100 crore drug racket: Accused transported drugs in vehicle with Chandigarh number plate
NPPA fixes retail price of 2 formulations: November 2021
Procedure to obtain license for Commercial Testing Laboratories
NPPA fixes retail price of 47 formulations: November 2021
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
